Management of Non-Anion-Gap Metabolic Acidosis (NAGMA) in CKD
Maintain serum bicarbonate ≥22 mmol/L in CKD patients with metabolic acidosis using oral sodium bicarbonate supplementation (2-4 g/day or 25-50 mEq/day) and/or increased dialysate bicarbonate concentration in dialysis patients. 1
Monitoring Strategy
- Measure serum bicarbonate monthly in maintenance dialysis patients 1
- For non-dialysis CKD stages 3-5, monitor bicarbonate levels at least twice annually 2
- NAGMA is the predominant form of metabolic acidosis in CKD, particularly as kidney function declines 3
Treatment Approach
For Dialysis Patients
Increase dialysate bicarbonate concentration to 38 mmol/L to safely raise predialysis serum bicarbonate levels 1. This can be combined with oral sodium bicarbonate supplementation if needed.
For Non-Dialysis CKD Patients
Oral sodium bicarbonate: 2-4 g/day (25-50 mEq/day) is the standard treatment 1
However, the 2024 KDIGO guidelines have significantly modified recommendations based on recent evidence showing limited benefit of bicarbonate supplementation on hard outcomes 4. Current guidance now recommends bicarbonate supplementation only when serum bicarbonate is <18 mmol/L 4, representing a major shift from previous practice.
Dietary Modification
Increase plant-based foods and reduce animal-sourced protein intake to decrease dietary acid load 5, 6, 7. This approach:
- Reduces endogenous acid production
- May slow CKD progression
- Avoids sodium loading from bicarbonate salts
- Particularly useful when sodium restriction is needed
Maintain protein intake at 0.8 g/kg/day in CKD stages 3-5 5 while emphasizing plant-based sources to reduce acid generation.
Clinical Rationale
Metabolic acidosis in CKD causes:
- Increased protein degradation and muscle wasting
- Decreased albumin synthesis
- Bone demineralization
- Accelerated CKD progression
- Increased hospitalization rates 1
Correction of acidosis has been associated with:
- Increased serum albumin
- Decreased protein degradation
- Improved branched-chain amino acid levels
- Reduced hospital stays in peritoneal dialysis patients 1
Important Caveats
The Bicarbonate Controversy
Recent large-scale trials have failed to demonstrate clear mortality or morbidity benefits from bicarbonate supplementation 4, leading to the restrictive 2024 KDIGO recommendations. The previous target of maintaining bicarbonate ≥22 mmol/L was based on observational data and surrogate outcomes (nutritional markers), not hard clinical endpoints.
Sodium Concerns
Oral sodium bicarbonate provides substantial sodium load (1 g NaHCO₃ = 12 mEq sodium). Monitor for:
- Blood pressure elevation
- Volume overload
- Worsening heart failure
Do not use sodium bicarbonate in patients with sodium-wasting nephropathy 5
When NOT to Treat Aggressively
- Bicarbonate 18-22 mmol/L: Consider dietary modification first 4
- Patients with volume overload or uncontrolled hypertension
- Those with limited life expectancy or frailty 5
Emerging Therapies
Veverimer (non-absorbed polymer that binds gastrointestinal HCl) is under investigation as an alternative to sodium-based alkali, avoiding sodium loading 6, 8, 9. This may be particularly useful in patients requiring sodium restriction.
Practical Algorithm
- Confirm NAGMA: Check anion gap (should be <12-15 mEq/L in CKD) 3
- Assess severity:
- Bicarbonate <18 mmol/L → Treat with oral bicarbonate
- Bicarbonate 18-22 mmol/L → Consider dietary modification
- Bicarbonate >22 mmol/L → Monitor only
- Choose intervention:
- Dialysis patients → Increase dialysate bicarbonate to 38 mmol/L
- Non-dialysis with sodium tolerance → Oral NaHCO₃ 25-50 mEq/day
- Sodium-sensitive or hypertensive → Dietary acid reduction (increase fruits/vegetables, reduce animal protein)
- Monitor response: Recheck bicarbonate in 1-3 months, adjust dose accordingly
The key shift in modern practice is treating only severe acidosis (bicarbonate <18 mmol/L) with alkali supplementation, while using dietary strategies for milder cases 4, reflecting the lack of proven benefit and potential harms of aggressive bicarbonate supplementation in recent trials.